MedTrace Logo

Trimodal Lung-Sparing Treatment of Pleural Mesothelioma

NCT00859495 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2020-08-25

Study results available
· View outcomes & findings →

Summary

The primary objective of the study is to determine the feasibility (as determined by lack of serious adverse events) and tolerability (as determined by patient's ability to complete the study) of a multimodal lung sparing regimen of surgery, interpleural and intravenous chemotherapy, and local P-32 irradiation for malignant pleural mesothelioma.

Conditions

  • Pleural Mesothelioma

Interventions

DRUG

Doxorubicin

A medication used in cancer chemotherapy, derived by chemical semisynthesis from a bacterial species.

DRUG

Cisplatin

Platinum-based antineoplastic

DRUG

Pemetrexed

Folate Analog Metabolic Inhibitor

RADIATION

Radiotherapy

Standard procedure given 3 weeks after last dose of chemotherapy

Sponsors & Collaborators

Principal Investigators

  • Robert N Taub, MD, PhD · Columbia University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00859495 on ClinicalTrials.gov